<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000631.v1.p1" parentStudy="phs000631.v1.p1" createDate="2013-06-26" modDate="2013-12-17">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Mark M. Wurfel, MD, PhD</td><td>University of Washington, Seattle, WA, USA</td></tr>
		<tr><td>Principal Investigator</td><td>Michael Matthay, MD</td><td>University of California, San Francisco, CA, USA</td></tr>
		<tr><td>Principal Investigator</td><td>Thomas Martin, MD</td><td>University of Washington, Seattle, WA, USA</td></tr>
		<tr><td>Principal Investigator</td><td>David Christiani</td><td>Harvard School of Public Health, Boston, MA, USA</td></tr>
		<tr><td>Principal Investigator</td><td>Aron Fisher, MD</td><td>University of Pennsylvania, Philadelphia, PA, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>ARDSnet and the iSPAAR Consortium: Genetic Studies</StudyNameEntrez>
	<StudyNameReportPage>ARDSnet and the iSPAAR Consortium: Genomic Basis of Susceptibility and Outcomes in Patients with the Acute Respiratory Distress Syndrome (ARDS)</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case-Control</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Acute Respiratory Distress Syndrome (ARDS)/ Acute Lung Injury (ALI) is a syndrome defined by the presence of acute hypoxemic respiratory failure, bilateral pulmonary infiltrates on chest radiograph, a known clinical risk factor (e.g. sepsis, pneumonia, trauma, gastric fluid aspiration, pancreatitis, massive transfusion), and the absence of physiologic or clinical evidence of congestive heart failure.</p> <p>The Identification of SNPs Predisposing to Altered ALI Risk (iSPAAR) study is a multi-institutional cooperative study, funded through the NHLBI Recovery Act, that assembled samples and phenotype information from existing cohorts.</p> <p>The consortium included samples from patients with ARDS from the NIH NHLBI ARDS Clinical Trials Network (ARDSNet). Samples were obtained from 3 interventional treatment trials in patients with ARDS, including the Fluid and Catheter Treatment Trial (FACTT), the Albuterol to Treat Acute Lung Injury (ALTA) trial, and the Omega-3 Fatty Acid/Antioxidant Supplementation for ALI trial (Omega).</p> <p>In addition to ARDSnet samples, samples from the other cohorts included cases of established ARDS but also controls: critically ill patients who were at-risk for ARDS but who did not develop ARDS during their hospital course. These cohorts included the Molecular Epidemiology of Acute Respiratory Distress (MEA) Study enrolled at the Harvard University/Massachusetts General Hospital, the Systemic Inflammatory Immune Response Syndrome (SIRS) Patient Database and ICU Traumatic Injury cohorts from Harborview Medical Center, and cohorts collected from the ALI research programs at the University of Pennsylvania and the University of California, San Francisco.</p> <p><b>The Cohort is utilized in the following dbGaP sub-studies.</b> To view genotypes, other molecular data, and derived variables collected in these sub-studies, please click on the following sub-studies below or in the "Sub-studies" box located on the right hand side of this top-level study page <a href="study.cgi?study_id=phs000631">phs000631</a> ARDSnet iSPAAR Consortium. <ul> <li><a href="study.cgi?study_id=phs000334">phs000334</a> ESP_LungGO_ALI </li> <li><a href="study.cgi?study_id=phs000686">phs000686</a> ALI_GeneticRisk </li> </ul> </p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Inclusions:</p> <p> <ol> <li>Caucasian</li> <li>Controls: patients at-risk for development of ARDS based on the presence of an ARDS risk factor (e.g., sepsis, pneumonia, trauma, aspiration, pancreatitis, massive transfusion) but who did not develop ARDS during their hospital course.</li> <li>Cases: patients with ARDS as defined by: 1) acute onset with P/F &#60;300, 2) bilateral chest infiltrates on chest radiograph, 3) absence of clinical evidence for left atrial hypertension, and 4) use of invasive positive pressure mechanical ventilation.</li> </ol></p> <p>Exclusions:</p> <p> <ol> <li>Metastatic cancer</li> <li>Hemodialysis dependence</li> <li>Hepatic failure</li> <li>Immunosuppression</li> <li>Burns</li> <li>Pregnancy</li> <li>Clinical evidence of elevated left atrial pressures</li> </ol> </p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="17133182"/>
		</Publication>
		<Publication>
			<Pubmed pmid="16714767"/>
		</Publication>
		<Publication>
			<Pubmed pmid="22307571"/>
		</Publication>
		<Publication>
			<Pubmed pmid="21976613"/>
		</Publication>
		<Publication>
			<Pubmed pmid="21562125"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Respiration Disorders"/>
		<Disease vocab_source="MESH" vocab_term="Sepsis"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Mark M. Wurfel, MD, PhD</AttName>
			<Institution>University of Washington, Seattle, WA, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Michael Matthay, MD</AttName>
			<Institution>University of California, San Francisco, CA, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Thomas Martin, MD</AttName>
			<Institution>University of Washington, Seattle, WA, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>David Christiani</AttName>
			<Institution>Harvard School of Public Health, Boston, MA, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Aron Fisher, MD</AttName>
			<Institution>University of Pennsylvania, Philadelphia, PA, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Grant O&#39;Keefe</AttName>
			<Institution>University of Washington, Seattle, WA, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>RC2 HL101779</AttName>
			<Institution>National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>P50 HL073996</AttName>
			<Institution>National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>R01 HL060710</AttName>
			<Institution>National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>P01 HL079063</AttName>
			<Institution>National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>R01 GM066946</AttName>
			<Institution>National Institute of General Medical Sciences, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source: ARDS Clinical Trials Network">
			<AttName>HHSN268200536165C</AttName>
			<Institution>National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source: ARDS Clinical Trials Network">
			<AttName>HHSN268200536166C</AttName>
			<Institution>National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source: ARDS Clinical Trials Network">
			<AttName>HHSN268200536167C</AttName>
			<Institution>National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source: ARDS Clinical Trials Network">
			<AttName>HHSN268200536168C</AttName>
			<Institution>National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source: ARDS Clinical Trials Network">
			<AttName>HHSN268200536169C</AttName>
			<Institution>National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source: ARDS Clinical Trials Network">
			<AttName>HHSN268200536170C</AttName>
			<Institution>National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source: ARDS Clinical Trials Network">
			<AttName>HHSN268200536171C</AttName>
			<Institution>National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source: ARDS Clinical Trials Network">
			<AttName>HHSN268200536172C</AttName>
			<Institution>National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source: ARDS Clinical Trials Network">
			<AttName>HHSN268200536173C</AttName>
			<Institution>National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source: ARDS Clinical Trials Network">
			<AttName>HHSN268200536174C</AttName>
			<Institution>National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source: ARDS Clinical Trials Network">
			<AttName>HHSN268200536175C</AttName>
			<Institution>National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source: ARDS Clinical Trials Network">
			<AttName>HHSN268200536176C</AttName>
			<Institution>National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source: ARDS Clinical Trials Network">
			<AttName>HHSN268200536177C</AttName>
			<Institution>National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source: ARDS Clinical Trials Network">
			<AttName>HHSN268200536178C</AttName>
			<Institution>National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source: ARDS Clinical Trials Network">
			<AttName>HHSN268200536179C</AttName>
			<Institution>National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyURLs>
		<Url name="NHLBI ARDS Network" url="http://www.ardsnet.org/"/>
	</StudyURLs>
	<StudyHistory><![CDATA[
<p>ARDS is an acute inflammatory lung disorder caused by a range of etiologies (e.g. sepsis, pneumonia, trauma, gastric fluid aspiration, pancreatitis, massive transfusion) associated with high mortality (20-25%). There are no specific treatments other than supportive care in the intensive care unit. ARDS can occur in people of all ages, but not all people with risk factors will develop ARDS. Susceptibility, in terms of which patients will (a) develop ARDS or (b) die if they get it, is not understood.</p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="HMB" longName="Health/Medical/Biomedical"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NHLBI</DacName>
      <DacFullName>National Heart, Lung, and Blood Institute DAC</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000631.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>12</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000631.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000631.v1.p1" FileName="GenomicRiskforALI_DUC_FINAL.071712.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Health/Medical/Biomedical</ConsentName>
        <ConsentAbbrev>HMB</ConsentAbbrev>
        <UseLimitation>Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.
The informed consent document signed by the iSPAAR Study Participants allows use of these data by investigators employed by non-profit and for-profit organizations. These data may be used by private companies in the development of diagnostics and therapeutics under the current consent. This consent group does not require IRB approval.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="999">
        <ConsentName>Exchange Area</ConsentName>
        <ConsentAbbrev>EA</ConsentAbbrev>
        <UseLimitation>The informed consent document signed by the ALI Cohort Study Participants allows use of these data by investigators employed by non-profit and for-profit organizations. These data may be used by private companies in the development of diagnostics and therapeutics under the current consent.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
